Israel and Waltham, Massachusetts-based Eloxx Pharmaceuticals Ltd, a developer of treatments that focus on genetic diseases caused by nonsense mutations, has appointed Gregory Weaver as chief financial officer. He is the former CFO at Prometic Life Sciences. The investors included Korea Investment Partners, DSC Investments, Pontifax Venture Capital and Quark Venture.
SAN DIEGO, TEL AVIV, Israel and BOSTON, Sept. 26, 2017 /PRNewswire/ — Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company developing novel small molecule medicines for genetic diseases caused by nonsense mutations, today announced the appointment of Gregory Weaver, M.B.A., as Chief Financial Officer. Mr. Weaver is a seasoned financial executive with more than 30 years of experience in leading business and financial operations for private and public companies, including financing transactions, strategic planning, investor relations, and business development initiatives.
“Greg brings a wealth of biopharmaceutical sector experience, both as a CFO and Board Member, as well as the financial and business acumen ideally suited to Eloxx,” said Dr. Silvia Noiman, CEO and co-founder of Eloxx. “Greg’s broad industry perspective, robust understanding of the crucial operational aspects of a growing company, and his demonstrated ability to manage multiple strategic functions will be essential as we focus our efforts on building a leading organization that creates value and improves the lives of patients suffering from devastating genetic diseases.”
During his career, Mr. Weaver has been instrumental in raising more than $900 million in private and public equity and debt financing for both U.S. and international life science companies. Prior to joining Eloxx, Mr. Weaver served as Chief Financial Officer of Prometic Life Sciences, where he led the Company’s global financial team. Previously, Mr. Weaver served as Executive Vice President and Chief Financial Officer of Oryzon Genomics where he managed the Company’s IPO financing. Earlier in his career, Mr. Weaver served as Chief Financial Officer of several other life sciences companies, including Fibrocell Science, Celsion Corp., Poniard Pharmaceuticals, and Sirna Therapeutics. In addition, Mr. Weaver currently serves as a member of the Board of Directors of Egalet Corporation and Atossa Genetics. Mr. Weaver received his M.B.A. from Boston College, a B.S. in accounting from Trinity University, and U.S. CPA certification.
Mr. Weaver stated, “I am impressed with the operational and clinical progress Eloxx has made since its founding. I believe the Company’s promising therapeutic candidates may offer significant advantages to treating diseases and conditions caused by nonsense mutations relative to other approaches. I look forward to applying my expertise to help Eloxx achieve its full potential.”
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. Nonsense mutations are a class of gene defect resulting in absent or truncated nonfunctional proteins, accounting for some of the most severe phenotypes in genetic diseases. Eloxx’s lead product candidate, ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins missing in patients with nonsense mutations. ELX-02 is entering Phase 2 clinical development for Cystic Fibrosis. Additional disease targets include Mucopolysaccharidosis Type I (MPS I), Rett Syndrome, and Duchenne Muscular Dystrophy (DMD) and Cystinosis. Eloxx Pharmaceuticals was founded in 2013 and maintains offices in Boston, MA, and Rehovot, Israel.